Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				100798-HMO-CTIL NCT00148993


2.		Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Approved-not yet active				55 and over				Other				191199-HMO-CTIL NCT00162513


3.		A Phase I/Ii Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Under 21				Other				22053 NCT00703222


4.		Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Approved-not yet active				18 and over				Other				0359-08-HMO-CTIL NCT00722228

Last Modified: 11/12/2008 First Published: 1/18/2008


5.		Phase II Study of Vaccine Therapy Comprising Allogeneic Tumor Cells and GM.CD40L in Combination With Tretinoin and Cyclophosphamide in Patients Who Have Completed First-Line Chemotherapy for Metastatic Adenocarcinoma of the Lung

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MCC-14744 MCC 14744, MCC-104490, MCC-0534-NE, NIH-OBA-0608-801, NCT00601796


6.		Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CTN-0505 UKIRB 06-0716-F3R, ULIRB 065.07, CIRB 1079747, NCT00654030

First Published: 12/23/2008


7.		Phase II Randomized Study of an Allogeneic Prostate Cancer Cell Vaccine With Versus Without Autologous Myeloid Dendritic Cells in Patients With Androgen-Independent Non-Metastatic Prostate Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				18 and over				NCI				MAYO-MC0554 MC0554, MAYO-06-004659, NCT00814892


8.		Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				40 and over				Other				06-275 NCT00487305

Last Modified: 11/18/2008 First Published: 4/8/2008


9.		Phase I Study of Adjuvant Cyclophosphamide and Adjuvant Vaccine Therapy Comprising Allogeneic Colon Cancer Cells and K562/GM-CSF Cells in Patients With Resected Hepatic Metastases Secondary to Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				JHOC-J0745 J0745, JHOC-NA_00009345, NCT00656123

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute